NASDAQ:KPRX • US49721T5074
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for KIORA PHARMACEUTICALS INC (KPRX).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2025-09-02 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-03-28 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-11-12 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-08-22 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-07-23 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-05-20 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-03-27 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-02-09 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-11-13 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-11-06 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-08-24 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-08-14 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-08-09 | Maxim Group | Maintains | Buy -> Buy |
| 2023-05-12 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-03-24 | HC Wainwright & Co. | Reiterate | Buy |
| 2023-02-09 | Maxim Group | Upgrade | Hold -> Buy |
| 2023-02-08 | Ladenburg Thalmann | Reiterate | Buy |
| 2023-02-08 | HC Wainwright & Co. | Reiterate | Buy |
| 2022-08-25 | Ladenburg Thalmann | Initiate | Buy |
| 2022-08-15 | Maxim Group | Downgrade | Buy -> Hold |
| 2022-07-11 | HC Wainwright & Co. | Maintains | Buy |
| 2022-04-19 | HC Wainwright & Co. | Maintains | Buy |
| 2022-01-19 | Maxim Group | Initiate | Buy |
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 16.02M | 1.53M -90.45% | 1.53M | -100.00% | 23.231M | 68.735M 195.88% | 171.13M 148.97% | 243.19M 42.11% | 306.5M 26.03% | |||
| EBITDA YoY % growth | -12.27M -20.89% | -10.631M 13.36% | 6.538M 161.50% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -12.31M -20.69% | -10.683M 13.22% | 6.518M 161.02% | -8.545M -231.09% | -19.208M -124.79% | -27.336M -42.32% | -6.495M 76.24% | 32.954M 607.35% | 118.96M 260.99% | 182.4M 53.33% | 243.24M 33.36% | |
| Operating Margin | N/A | N/A | 40.69% | -558.47% | -1,255.40% | N/A | -27.96% | 47.94% | 69.51% | 75.00% | 79.36% | |
| EPS YoY % growth | -232.11 61.43% | -28.35 87.79% | 1.04 103.67% | -1.74 -267.71% | -2.27 -30.41% | -2.10 7.62% | -0.19 90.78% | 5.65 3,015.79% | 16.49 191.88% | N/A | N/A |
All data in USD
| Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.68 34.29% | -0.46 11.73% | -0.70 -30.33% | -0.55 -5,608.00% | -0.57 16.42% | -0.56 -22.22% | -0.58 17.39% | -0.43 22.22% | -0.45 21.43% |
| Revenue Q2Q % growth | 1.53M | 1.53M | -100.00% | N/A | N/A | N/A | N/A | ||
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -2.913M -13.59% | -3.24M -39.01% | -4.978M -107.73% | -5.392M -578.72% | -5.599M -92.19% | -6.038M -86.40% | -6.302M -26.60% | -6.826M -26.60% | -7.089M -26.62% |
All data in USD
7 analysts have analysed KPRX and the average price target is 12.24 USD. This implies a price increase of 521.32% is expected in the next year compared to the current price of 1.97.
KIORA PHARMACEUTICALS INC (KPRX) will report earnings on 2026-05-07.
The consensus EPS estimate for the next earnings of KIORA PHARMACEUTICALS INC (KPRX) is -0.68 USD and the consensus revenue estimate is 1.53M USD.
The number of analysts covering KIORA PHARMACEUTICALS INC (KPRX) is 7.